INTS

Intensity Therapeutics, Inc. INTS

INTS
Intensity Therapeutics, Inc. IBIO
iBio, Inc. IMNN
Imunon, Inc. AEON
AEON Biopharma, Inc. DWTX
Dogwood Therapeutics, Inc. CTXR
Citius Pharmaceuticals, Inc. LYRA
Lyra Therapeutics, Inc. THAR
Tharimmune, Inc. ATHA
Athira Pharma, Inc. RNAZ
TransCode Therapeutics, Inc.

Net profit

EBITDA

P/E Ratio

Capitalization

Performance

Periode INTS IBIO IMNN AEON DWTX CTXR LYRA THAR ATHA RNAZ
6M -85.11 % -13.32 % -62.85 % 175.00 % 62.20 % 40.55 % 63.48 % 187.27 % 62.01 % 48.80 %
YTD -84.17 % -64.90 % -69.52 % -97.22 % 141.04 % -64.18 % -30.37 % 54.15 % -32.55 % -78.53 %
1Y -91.61 % -70.19 % -68.00 % -98.61 % 36.57 % -86.50 % -37.39 % 26.40 % -18.46 % -96.62 %
3Y -95.35 % -98.19 % -79.62 % -99.83 % -31.25 % -95.08 % -96.83 % -98.72 % -89.40 % -100.00 %
5Y -95.35 % -99.92 % -96.56 % -99.83 % -98.55 % -94.99 % -98.86 % -99.76 % -97.97 % -100.00 %
10Y -95.35 % -99.98 % -99.92 % -99.83 % -98.55 % -99.70 % -99.19 % -99.76 % -97.83 % -100.00 %
From the beginning -95.35 % -99.98 % -100.00 % -99.83 % -98.55 % -99.63 % -99.19 % -99.76 % -97.83 % -100.00 %

Dividend